GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Asymchem Laboratories Tianjin Co Ltd (HKSE:06821) » Definitions » Cash Flow from Discontinued Operations

Asymchem Laboratories Tianjin Co (HKSE:06821) Cash Flow from Discontinued Operations : HK$0 Mil (TTM As of Mar. 2025)


View and export this data going back to 2021. Start your Free Trial

What is Asymchem Laboratories Tianjin Co Cash Flow from Discontinued Operations?

Cash flow from discontinued operations is the cash received by a company that comes from the sale of part of business.

Asymchem Laboratories Tianjin Co's cash flow from discontinued operations for the three months ended in Mar. 2025 was HK$0 Mil. It means Asymchem Laboratories Tianjin Co received HK$0 Mil from the sale of part of business quarterly. Asymchem Laboratories Tianjin Co's cash flow from discontinued operations for the trailing twelve months (TTM) ended in Mar. 2025 was HK$0 Mil.

Asymchem Laboratories Tianjin Co Cash Flow from Discontinued Operations Historical Data

The historical data trend for Asymchem Laboratories Tianjin Co's Cash Flow from Discontinued Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Asymchem Laboratories Tianjin Co Cash Flow from Discontinued Operations Chart

Asymchem Laboratories Tianjin Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cash Flow from Discontinued Operations
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Asymchem Laboratories Tianjin Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cash Flow from Discontinued Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Asymchem Laboratories Tianjin Co Cash Flow from Discontinued Operations Calculation

Cash received by a company that comes from the sale of part of business.

Cash Flow from Discontinued Operations for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Asymchem Laboratories Tianjin Co Cash Flow from Discontinued Operations Related Terms

Thank you for viewing the detailed overview of Asymchem Laboratories Tianjin Co's Cash Flow from Discontinued Operations provided by GuruFocus.com. Please click on the following links to see related term pages.

Asymchem Laboratories Tianjin Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Asymchem Laboratories Tianjin Co Ltd (HKSE:06821) » Definitions » Cash Flow from Discontinued Operations
Comparable Companies
SHSE:688278 SHSE:688336 SZSE:002007 SZSE:301301 SZSE:300255 SHSE:688266 SZSE:300759 SHSE:600161 SHSE:688578 SHSE:603233 VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
7K90:Germany 002821:China
Address
No. 6 Dongting 3rd Street, Economic and Technological Development Zone, Tianjin, CHN, 300457
Website
https://www.asymchem.com
Asymchem Laboratories Tianjin Co Ltd is a China-based company, a technology-driven provider of Contract Development and manufacturing organization solutions throughout the drug development and manufacturing process. The Group provides clinical-stage CDMO solutions, commercial-stage CDMO solutions, and emerging services. Its operations relate to contract development and manufacturing, which focuses on innovation and commercial application of pharmaceutical technology. It has geographic areas in the Chinese Mainland and Overseas.
Executives
Schroders Plc 2102 Investment manager
Citigroup Inc. 2201 Interest of corporation controlled by you
Jpmorgan Chase & Co. 2201 Interest of corporation controlled by you
Norges Bank 2101 Beneficial owner
Barclays Plc 2201 Interest of corporation controlled by you
Fmr Llc 2201 Interest of corporation controlled by you
Fidelity Investment Trust 2101 Beneficial owner
Springhill Fund Asset Management (hk) Company Limited 2102 Investment manager
Springhill Fund Limited 2201 Interest of corporation controlled by you
Springhill Global Feeder Fund Limited 2201 Interest of corporation controlled by you
Springhill Master Fund Limited 2101 Beneficial owner
Morgan Stanley 2201 Interest of corporation controlled by you
Hhlr Advisors, Ltd. 2102 Investment manager
Hhlr Fund, L.p. 2101 Beneficial owner
Jpmorgan Asset Management (asia Pacific) Limited 2102 Investment manager

Asymchem Laboratories Tianjin Co Headlines

No Headlines